amikacin sopharma
sopharma ad - amikacinas - injekcinis tirpalas - 250 mg/ml - amikacin
kanamycin panpharma
panpharma - kanamicinas - milteliai injekciniam tirpalui - 1 g - kanamycin
furosemid polpharma
pharmaceutical works polpharma s.a. - furozemidas - tabletės - 40 mg - furosemide
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 10 mg - rivaroxaban
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 15 mg - rivaroxaban
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas - plėvele dengtos tabletės - 20 mg - rivaroxaban
rivaroxaban g.l. pharma
g.l. pharma gmbh - rivaroksabanas+rivaroksabanas - plėvele dengtos tabletės - 15 mg + 20 mg - rivaroxaban
pirantelis polpharma [pirantelis medana]
zakłady farmaceutyczne polpharma s.a. - pirantelis - geriamoji suspensija - 250 mg/5 ml - pyrantel
dasatinib accordpharma
accord healthcare s.l.u. - dasatinibas - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antinavikiniai vaistai - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
gentamicin sopharma
sopharma ad - gentamicinas - injekcinis ar infuzinis tirpalas - 40 mg/ml - gentamicin